Novavax/NVAX

$5.39

6.47%
-
1D1W1MYTD1YMAX

About Novavax

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.

Ticker

NVAX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Jacobs

Employees

1,543

Headquarters

Gaithersburg, United States

Novavax Metrics

BasicAdvanced
$754.35M
Market cap
-
P/E ratio
-$5.53
EPS
1.59
Beta
-
Dividend rate

What the Analysts think about Novavax

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
185.71% upside
High $38.00
Low $4.00
$5.39
Current price
$15.40
Average price target

Novavax Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-61.2% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$291.3M
55.86%
Net income
$-178.3M
36.42%
Profit margin
-61.2%
-12.48%

Novavax Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 221.19%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$3.41
$0.58
-$1.26
-$1.44
-
Expected
-$3.46
-$1.39
-$1.83
-$0.45
-$0.95
Surprise
-1.5%
-141.83%
-31.21%
221.19%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Novavax stock

Buy or sell Novavax stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing